HPV16 E2 is an immediate early marker of viral infection, preceding E7 expression in precursor structures of cervical carcinoma.
The viral E2 gene product plays a crucial role in the human papillomavirus (HPV) vegetative cycle by regulating both transcription and replication of the viral genome. E2 is a transcriptional repressor of the E6 and E7 viral oncogenes for HPV types 16 and 18, which are involved in cervical cancers. Using new polyclonal antibodies against the HPV16 E2 protein, we showed that E2 is expressed at various precursor stages of cervical carcinoma by immunohistochemistry on paraffin-embedded clinical samples. E2 was found to be highly expressed in the nuclei and cytoplasm of cells forming the intermediate and upper layers of cervical intraepithelial neoplasia (CIN). We could show that the expressions of E2 and p16(INK4a) (surrogate marker for oncogenic E7 expression) were exclusive in most of the cases, thus implying that E2 is not expressed together with high levels of E7. Moreover, we found that E2 is expressed in a subset of columnar cells adjacent to the CIN. We could show that expression of E2 is topologically distinct from the proliferation markers p63 and Ki67, whereas it coincides with the expression of cytokeratin K13, a marker of squamous cell differentiation. Expression of E2 also topologically coincides with episomal amplification of viral genomes in the upper layers of CIN1. These in vivo data thus validate previous assumptions of the crucial role of E2 in the early steps of HPV infection and of its negative link with expression of the viral E6 and E7 oncogenes.
Papillomavirus Regulation and Cancer, Institute of Medical Biology, BMSI, A*Star, Immunos, Singapore.
Yuezhen
Y
Xue
Sophie
S
Bellanger
Wenying
W
Zhang
Diana
D
Lim
Jeffrey
J
Low
Declan
D
Lunny
Françoise
F
Thierry
D000906:Antibodies / Q000737:chemistry; D000918:Antibody Specificity; D014408:Biomarkers, Tumor / Q000032:analysis*; D004261:DNA Replication; D004268:DNA-Binding Proteins / Q000032:analysis* / Q000096:biosynthesis / Q000276:immunology; D005260:Female; D052162:Human papillomavirus 16 / Q000235:genetics / Q000302:isolation & purification / Q000378:metabolism*; D006801:Humans; D007150:Immunohistochemistry; D009856:Oncogene Proteins, Viral / Q000032:analysis* / Q000096:biosynthesis / Q000276:immunology; D050725:Papillomavirus E7 Proteins / Q000032:analysis* / Q000096:biosynthesis / Q000276:immunology; D030361:Papillomavirus Infections / Q000175:diagnosis / Q000821:virology*; D016612:Paraffin Embedding; D002583:Uterine Cervical Neoplasms / Q000175:diagnosis / Q000821:virology*; D014779:Virus Replication; D002578:Uterine Cervical Dysplasia / Q000175:diagnosis / Q000821:virology*
D000906:Antibodies; D014408:Biomarkers, Tumor; D004268:DNA-Binding Proteins; C054855:E2 protein, Human papillomavirus type 16; D009856:Oncogene Proteins, Viral; D050725:Papillomavirus E7 Proteins; C059731:oncogene protein E7, Human papillomavirus type 16